6972-78-7

Usage

Uses

Used in Antimicrobial Applications:
6-AMINO-1-METHYL-5-NITROSOURACIL is used as an antimicrobial agent for its ability to inhibit the growth of various microorganisms, making it a potential candidate for use in pharmaceuticals and other industries where microbial control is necessary.
Used in Platinum Complexation:
6-AMINO-1-METHYL-5-NITROSOURACIL is used as a complexing agent for platinum (II), which can be utilized in various applications such as the development of new catalysts, sensors, or materials with unique properties. The complexation with platinum (II) can also enhance the stability and reactivity of the compound in different chemical reactions.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 6-AMINO-1-METHYL-5-NITROSOURACIL is used as an active pharmaceutical ingredient or as a key intermediate in the synthesis of various drugs. Its antimicrobial activity and complexation properties with platinum (II) make it a valuable compound for the development of new therapeutic agents.
Used in Chemical Research:
6-AMINO-1-METHYL-5-NITROSOURACIL is used as a research compound in chemical laboratories for studying its properties, reactivity, and potential applications. Its unique structure and functional groups make it an interesting subject for research in organic chemistry, materials science, and related fields.

InChI:InChI=1/C5H6N4O3/c1-9-3(6)2(8-12)4(10)7-5(9)11/h6H2,1H3,(H,7,10,11)

Upstream product

• 59653-14-4 N-(cyano-hydroxyimino-acetyl)-N'-methyl-urea 
• 17743-03-2 1-Methyl-6-imino-uracil 
• 2434-53-9 6-amino-1-methyluracil 
• 623-59-6 N-acetyl-N'-methylurea 
• 6972-77-6 N-cyanoacetyl-N'-methyl-urea 

Downstream Products

• 14785-95-6 3-methyl-4-amino-5-formylamino-2,6-dioxypyrimidine 
• 6972-82-3 5,6-diamino-1-methyluracil 
• 1076-22-8 3-methylxanthine 
• 64233-24-5 1-methyl-6-phenylpteridine-2,4-dione 
• 2850-34-2 3-methyl-8-phenylxanthine 
• 453591-12-3 3-methyl-6-methylsulfanyl-8-phenyl-3,7-dihydro-purin-2-one 
• 453591-08-7 3-methyl-8-phenyl-6-thioxo-1,3,6,7-tetrahydro-purin-2-one 
• 343362-39-0 6-amino-1-methyl-5-[3-phenyl-(E,2E)-2-propenylidenamino]-1,2,3,4-tetrahydro-2,4-pyrimidindione 
• 453591-06-5 3-methyl-8-styrylxanthine 
• 453591-07-6 3-Methyl-8-((E)-styryl)-6-thioxo-1,3,6,7-tetrahydro-purin-2-one 
• 453591-11-2 3-Methyl-6-methylsulfanyl-8-((E)-styryl)-3,7-dihydro-purin-2-one 
• 453591-30-5 6-(1-hydroxymethyl-propylamino)-3-methyl-8-phenyl-3,7-dihydro-purin-2-one 
• 453591-31-6 6-((R)-1-Hydroxymethyl-propylamino)-3-methyl-8-phenyl-3,7-dihydro-purin-2-one 
• 453591-32-7 6-((S)-1-Hydroxymethyl-propylamino)-3-methyl-8-phenyl-3,7-dihydro-purin-2-one 

Relevant academic research and scientific papers

Linagliptin intermediate compound IV

The invention belongs to the field of pharmaceutical chemicals, and discloses a linagliptin intermediate IV and a novel route for synthesizing an important linagliptin intermediate from the linagliptin intermediate IV. The linagliptin intermediate IV synthesized in the invention has the advantages of high yield, simple operation, substantial reduction of production cost, suitableness for industrial production; and the synthesis route solves the problems of self-coupling of linagliptin intermediates and generation of large impurities in the prior art.

Novel, Dual Target-Directed Annelated Xanthine Derivatives Acting on Adenosine Receptors and Monoamine Oxidase B

Annelated purinedione derivatives have been shown to act as possible multiple-target ligands, addressing adenosine receptors and monoaminooxidases. In this study, based on our previous results, novel annelated pyrimido- and diazepino[2,1-f]purinedione derivatives were designed as dual-target-directed ligands combining A2A adenosine receptor (AR) antagonistic activity with blocking monoamine oxidase B. A library of 19 novel compounds was synthesized and biologically evaluated in radioligand binding studies at AR subtypes and for their ability to inhibit MAO-B. This allowed 9-(2-chloro-6-fluorobenzyl)-3-ethyl-1-methyl-6,7,8,9-tetrahydropyrimido[2,1-f]purine-2,4(1H,3H)-dione (13 e; Ki human A2AAR: 264 nM and IC50 human MAO-B: 243 nM) to be identified as the most potent dual-acting ligand from this series. ADMET parameters were estimated in vitro, and analysis of the structure-activity relationships was complemented by molecular-docking studies based on previously published X-ray structures of the protein targets. Such dual-acting ligands, by selectively blocking A2A AR, accompanied by the inhibition of dopamine metabolizing enzyme MAO-B, might provide symptomatic and neuroprotective effects in, among others, the treatment of Parkinson disease.

Synthesis, radiolabelling and initial biological characterisation of 18F-labelled xanthine derivatives for PET imaging of Eph receptors

Eph receptor tyrosine kinases, particularly EphA2 and EphB4, represent promising candidates for molecular imaging due to their essential role in cancer progression and therapy resistance. Xanthine derivatives were identified to be potent Eph receptor inhibitors with IC50 values in the low nanomolar range (1-40 nm). These compounds occupy the hydrophobic pocket of the ATP-binding site in the kinase domain. Based on lead compound 1, we designed two fluorine-18-labelled receptor tyrosine kinase inhibitors ([18F]2/3) as potential tracers for positron emission tomography (PET). Docking into the ATP-binding site allowed us to find the best position for radiolabelling. The replacement of the methyl group at the uracil residue ([18F]3) rather than the methyl group of the phenoxy moiety ([18F]2) by a fluoropropyl group was predicted to preserve the affinity of the lead compound 1. Herein, we point out a synthesis route to [18F]2 and [18F]3 and the respective tosylate precursors as well as a labelling procedure to insert fluorine-18. After radiolabelling, both radiotracers were obtained in approximately 5% radiochemical yield with high radiochemical purity (>98%) and a molar activity of >10 GBq μmol-1. In line with the docking studies, first cell experiments revealed specific, time-dependent binding and uptake of [18F]3 to EphA2 and EphB4-overexpressing A375 human melanoma cells, whereas [18F]2 did not accumulate at these cells. Since both tracers [18F]3 and [18F]2 are stable in rat blood, the novel radiotracers might be suitable for in vivo molecular imaging of Eph receptors with PET.

Linagliptin intermediate compound V

The invention belongs to the field of pharmaceutical chemicals, and provides a linagliptin intermediate compound V and an important intermediate for synthesizing linagliptin by using the intermediateV. The method solves the problems of self-coupling of linagliptin intermediates and generation of large impurities in the prior art, and the synthesized novel intermediate compound V has the advantages of high yield, simple operation, significantly reduced production cost, and suitableness for industrial production.

Substituted xanthine compound and its preparation and use (by machine translation)

The invention discloses substituted xanthine compounds, a preparation method and applications thereof, and specifically relates to compounds represented by the formula (I), stereo isomers and pharmaceutically acceptable salts thereof, wherein the R1 and R2 are defined in the description. The invention also relates to a pharmaceutical composition containing the compounds, an application of the pharmaceutical composition in preparation of drugs for treating diseases or symptoms caused by high activity of DPP-IV or overexpression of DPP-IV, and a method using the pharmaceutical composition to treat related diseases. The provided compounds can effectively inhibit the activity of DPP-IV.

Xanthine compound and pharmaceutical composition and application thereof

The invention discloses a xanthine derivative as shown in the formula (I) and a pharmaceutical composition and application thereof. The xanthine derivative is prepared from a compound as shown in theformula (I) or a stereoisomer, a geometrical isomer, a hydrate or a solvate thereof, or a pharmaceutically acceptable salt or prodrug as shown in the description. The invention also relates to application of the compound as shown in the formula (I) and the pharmaceutical composition thereof as a DPP-4 inhibitor, and especially application in preparation of medicines for treating and/or preventingmetabolic disorder diseases such as diabetes.

7,8-substituted-3-methylxanthine compounds as well as preparation method and application thereof

The invention discloses 7,8-substituted-3-methylxanthine compounds as well as a preparation method and an application thereof. The compounds have the structural formula (I) shown in the description, wherein R is aliphatic hydrocarbon, an aromatic ring, an acyl-containing group, a hydroxyl-containing group or a sulfhydryl-containing group; R1 is C1-4 alkyl, halogen substituted C1-4 alkyl, C1-4 alkoxy, halogen, a cyano group, nitryl, acetyl, benzyl, benzyloxy, substituted or unsubstituted C1-4 alkylbenzene, a substituted or unsubstituted amino group, substituted guanidyl, a substituted or unsubstituted phosphate group, a substituted or unsubstituted sulfonic group, a substituted or unsubstituted long-chain fatty alkane or substituted or unsubstituted long-chain fatty amine. The compounds have good inhibition effects on PDE8 (phosphodiesterase type 8), PDE8 is also a potential target of the alzheimer's disease, vascular dementia and diabetes, the compounds take PDE8 as the target, and a drug prepared from the compounds has a better curative effect on alzheimer's disease, vascular dementia and diabetes as well.

Synthesis and evaluation of antitumour activities of novel fused tri-And tetracyclic uracil derivatives

Simple one-pot syntheses of indenopyrrolopyrimidines and indolopyrrolopyrimidines were achieved via the cyclocondensation of 6-Aminouracils and, respectively, ninhydrin and isatin in the presence of catalytic amounts of glacial acetic acid. Similarly, 5,6-diaminouracil derivatives were used as starting materials for the synthesis of indenopteridines and indolopteridines via their reaction with ninhydrin and isatin, respectively. The synthesised compounds were evaluated for antitumour activity against a human hepatocellular carcinoma cell line (HepG2), some showing antitumour activity comparable with 5-fluorouracil and imatinib.

A uracil nitroso amine based colorimetric sensor for the detection of Cu2+ ions from aqueous environment and its practical applications

A simple uracil nitroso amine based colorimetric chemosensor (UNA-1) has been synthesized and screened for its cation recognition ability. Sensor UNA-1 exhibited a high sensitivity and selectivity towards Cu2+ ions in aqueous medium in the presence of a wide range of other competing cations (Ag+, Al3+, Ba2+, Ca2+, Cd2+, Co2+, Cr3+, Cs+, Fe2+, Fe3+, Li+, Mg2+, Mn2+, Na+, Ni2+, Pb2+, Zn2+, Hg2+ and Sr2+). With Cu2+, the sensor UNA-1 gave a distinct color change from colorless to dark yellow by forming a complex of 1:1 stoichiometry. Furthermore, sensor UNA-1 was successfully utilized in the preparation of test strips and supported silica for the detection of Cu2+ ions from aqueous environment.

2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS

The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.